Press release

February 2021

Tremendous success for MedinCell’s €30 million capital increase for qualified investors
MedinCell announces a capital increase of a c.€30 million
MedinCell announces three new products entering regulatory development
02.02.2021
Publication of the 2021 financial calendar
02.01.2021

January 2021

MedinCell announces the transfer of its shares from compartment C to compartment B of Euronext Paris
01.22.2021
MedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
01.07.2020
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
01.07.2020

December 2020

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
12.17.2020
Live webcast of the Shareholders’ Meeting on Tuesday, December 15, 2020
12.10.2020
MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations
12.09.2020
Videoconference and publication of the 2020-2021 Half-Year Results, on December 9, 2020
12.02.2020

November 2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date
11.12.2020
Convening of the General Assembly: Proposal for the appointment of Elisabeth Kogan to the Supervisory Board
11.09.2020

September 2020

MedinCell initiates the first clinical trial of its Covid-19 prevention program
09.29.2020
MedinCell releases the results of its September 10, 2020 ordinary annual and extraordinary general meeting
09.11.2020

July 2020

Participation terms in the MedinCell Combined General Meeting and availability of preparatory documents
07.31.2020
MedinCell announces the availability of its 2019/2020 Universal Registration Document including the Annual Financial Report
07.29.2020

June 2020

MedinCell announces the great success of its capital increase and raises 15.6 M€
06.16.2020
MedinCell launches a capital increase of a minimum of 11 M€
06.15.2020
MedinCell successfully renegotiates the drawdown conditions of the last tranche of the EIB loan and secures an additional €5m of non-dilutive funding
MedinCell announces fiscal year consolidated results April 2019 – March 2020
06.04.2020

May 2020

MedinCell Secures €10.9 Million Non-Dilutive Financing
05.27.2020
Videoconference and publication of the results for the 2019-2020 financial year, on June 4, 2020
05.25.2020

April 2020

Adapt and overcome in response to the Covid-19 crisis
04.23.2020
MedinCell launches Regulatory Development of mdc-WWM Program
04.22.2020
Invitation to a webcast: adapting and acting in response to the Covid-19 crisis
04.20.2020
MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin
04.06.2020

March 2020

MedinCell receives $ 6.4 million grant from Unitaid to fight Malaria
03.25.2020

January 2020

US Pharma Development Veteran Dr. Richard Malamut Joins the Medical Advisory Board of MedinCell
01.28.2020
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
01.13.2020

December 2019

Publication of the activity report and financial information for the first half-year (April – Sept. 2019)
12.03.2019

November 2019

MedinCell receives $19 million grant for its mdc-WWM program
11.28.2019
MedinCell to publish its activity report and financial information of the first half of 2019-2020 on December 3, 2019

September 2019

MedinCell announces that mdc-CWM progresses as planned
09.25.2019
The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association
09.10.2019
MedinCell receives a new grant to develop a best-in-class longacting injectable product for HIV PrEP
09.05.2019

August 2019

MedinCell partners to address the untapped financial potential in Animal Health
08.28.2019
Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities
08.26.2019

July 2019

Publication of the 2018/2019 Annual Financial Report
07.31.2019
MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
07.23.2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development
07.09.2019

June 2019

MedinCell announces 2018/19 fiscal year results
06.04.2019

May 2019

Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019
05.21.2019

April 2019

MedinCell wins the #LetsgoFrance 2019 trophy in the category “France, a model of sustainable economy” (in French)
04.05.2019

March 2019

MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
03.11.2019

January 2019

MedinCell receives 2nd part of the grant from the Bill & Melinda Gates Foundation
01.24.2019
Publication of the 2019 Financial Calendar
01.15.2019

December 2018

Publication of the activity report and financial information for the first half-year (April – Sept. 2018)
12.03.2018

November 2018

Publication of the activity report and financial information for the first half-year on December 3, 2018
11.27.2018
Partial exercise of the over-allotment option and implementation of a liquidity agreement
11.05.2018

October 2018

Successful IPO of MedinCell
10.03.2018

September 2018

Teva to participate in MedinCell IPO
09.26.2018
Extension of the subscription period
09.25.2018
Launch of the Initial Public Offering
09.17.2018
Registration of the Document de base
09.05.2018

March 2018

EIB lends EUR 20m to MedinCell
03.22.2018

December 2017

MedinCell receives grant from the Bill & Melinda Gates Foundation
12.07.2017

October 2017

MedinCell announces investment by CM-CIC Innovation
10.19.2017